FDA Grants Priority Review for EGFR-Mutant Lung Cancer Drug Afatinib


A promising new drug for a subtype of non-small cell lung cancer (NSCLC) was recently granted priority review status by the U.S. Food and Drug Administration (FDA). If approved, afatinib would be the first drug on the market specifically for treating advanced or metastatic NSCLC associated with epidermal growth factor receptor (EGFR) mutations. Continue reading…


Targeted Therapy Success for NSCLC


A small, phase II clinical study has found a promising targeted therapy for the most common subtype of non-small cell lung cancer (NSCLC). A combination of chemotherapy and the MEK inhibitor drug selumetinib was more effective than chemotherapy alone in NSCLC patients with a mutation in the KRAS gene. Continue reading…